Press Releases

Circassia Announces Positive Outcome of European Decentralised Procedure for Approval of Its Fluticasone Propionate Equivalent of GSK’s FLIXOTIDE® pMDI

Click here to download the full press release – Product approvable in all reference product strengths – – Successful application based on in vitro demonstration of therapeutic equivalence – Oxford, UK – 24 November 2015:...

View details

Circassia Business Update

Click here to download the full business update — Good clinical progress across whole allergy and respiratory portfolio — — Strong commercial progress with significant NIOX® sales growth — — Robust balance sheet to fund...

View details

Interim Results for the Six Months Ended 30 June 2015

Click here to download the full 2015 interim results statement – Clinical programs on track – – Cat allergy phase III to report H1 2016; recruitment for grass allergy phase III to start H1 2016...

View details

Notice of Interim Results

Oxford, UK – 20 July 2015: Circassia Pharmaceuticals plc (“Circassia” or “the Company”) (LSE: CIR), a specialty biopharmaceutical company focused on allergy and asthma, will announce its interim results for the six months ended 30...

View details

Circassia’s Extended Offer Period for Aerocrine has Increased Acceptances to 97.2 Percent

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED IN IT IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN,...

View details

Completion of Acquisition of Prosonix Limited

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED IN IT IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN,...

View details

Results of the Placing and Open Offer

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED IN IT IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN,...

View details

Placing and Open Offer of New Ordinary Shares

Click here to download the full Placing and Open Offer announcement THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED IN IT IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY...

View details

Proposed Acquisitions of Aerocrine AB and Prosonix Limited Creating a World-Class Allergy and Asthma Specialty Pharma Business

Click here to download the full Proposed Acquisitions announcement NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN...

View details

Preliminary Results for the Year Ended 31 December 2014

Click here to download the full 2014 preliminary results statement – Strong clinical progress; Cat-SPIRE phase III study fully recruited – – Robust financial position; fully-funded to bring Cat-SPIRE to market – – Commercialisation preparations...

View details